Hemostemix Secures $480K Funding to Accelerate ACP-01 Autologous Stem Cell Therapy Development

Hemostemix Inc., the Calgary-based biotech pioneer focused on autologous stem cell treatments, has successfully closed a non-brokered private placement worth CAD $480,000. The funding round involved the issuance of 4 million common shares priced at $0.12 per share, marking a significant milestone for the company’s commercial expansion.

Capital Injection Fuels Clinical Pipeline Progress

The fresh capital injection arrives at a critical juncture for Hemostemix’s lead asset, ACP-01 (VesCell), an autologous angiogenic cell therapy designed to address multiple vascular and cardiac conditions. The company plans to deploy the proceeds toward advancing regulatory pathways, accelerating clinical development, and scaling commercialization efforts. This strategic funding round underscores investor confidence in the company’s technology platform and clinical trajectory.

Proven Clinical Track Record Strengthens Market Position

What sets Hemostemix apart is its extensive clinical validation. The company has completed seven Phase-level studies involving 318 patient subjects, with results published across eleven peer-reviewed scientific journals. ACP-01 has demonstrated efficacy in treating peripheral arterial disease, chronic limb threatening ischemia, ischemic cardiomyopathy, and nonischemic cardiomyopathy—establishing a broad therapeutic footprint in the cardiovascular space.

The Phase II trial for chronic limb threatening ischemia (CLTI) produced compelling real-world outcomes. When compared to the historical five-year mortality rate of 50% in CLTI patients, independent clinical analysis from leading Canadian academic institutions reported zero mortality, complete pain cessation, and 83% wound healing rates in patients tracked for up to 4.5 years. These results position ACP-01 as a potentially transformative treatment option for patients with limited therapeutic alternatives.

Broader Clinical Applications on the Horizon

Beyond vascular indications, Hemostemix is exploring ACP-01’s potential in treating congestive heart failure, angina, ischemic cardiomyopathy, and even vascular dementia. The company’s expansion into compassionate use programs under Florida’s regulatory framework represents another avenue for patient access while generating real-world evidence.

About the Company

Founded in 2003, Hemostemix earned recognition as a World Economic Forum Technology Pioneer. The company’s platform generates patient-derived stem cell therapies using blood-based precursor cells, offering a personalized medicine approach to degenerative vascular and cardiac diseases. With listings across TSXV (HEM), OTCQB (HMTXF), and Frankfurt Exchange (2VF0), the company maintains significant institutional visibility in both traditional and emerging markets.

All securities issued in this private placement are subject to standard statutory hold periods per applicable Canadian securities regulations and TSXV policies, pending final exchange acceptance.